Wyeth Ziac sales will be spurred by upcoming JNC VI guidelines, exec predicts at Oppenheimer conference.
Executive Summary
WYETH PREDICTS SPUR TO ZIAC SALES FROM UPCOMING JNC VI GUIDELINES on the management of hypertension, Wyeth-Ayerst Pharmaceuticals North America President Joseph Mahady told an Oppenheimer & Co. health care conference in New York City Oct. 28. Wyeth believes that the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure "will come out in favor of low dose beta blocker/diuretic as initial therapy," Mahady said. The JNC VI guidelines will be released Nov. 6. Wyeth markets the beta blocker bisoprolol as Zebeta and in combination with hydrochlorothiazide as Ziac.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth